JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2024, Vol. 26 ›› Issue (6): 818-824.DOI: 10.3969/j.issn.1671-2587.2024.06.018
Previous Articles Next Articles
WANG Jiaqi1, XIAO Jun2, LI Cuiying1,2
Received:
2024-07-01
Online:
2024-12-20
Published:
2024-12-20
CLC Number:
WANG Jiaqi, XIAO Jun, LI Cuiying. Research Progress of mTOR Pathway in Regulating Self-renewal and Differentiation of Hematopoietic Stem Cells[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 818-824.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.lcsxyjy.com/EN/10.3969/j.issn.1671-2587.2024.06.018
[1] OGAWA M.Differentiation and proliferation of hematopoietic stem cells[J]. Blood,1993,81(11):2844-2853. [2] ROSSI D J,SEITA J,CZECHOWICZ A,et al.Hematopoietic stem cell quiescence attenuates DNA damage response and permits DNA damage accumulation during aging[J]. Cell Cycle,2007,6(19):2371-2376. [3] DZIERZAK E,BIGAS A.Blood development: hematopoietic stem cell dependence and independence[J].Cell Stem Cell,2018,22(5):639-651. [4] LEE D H,KIM T S,LEE D J,et al.Mammalian sterile 20 kinase 1 and 2 are important regulators of hematopoietic stem cells in stress condition[J]. Sci Rep,2018,8(1):942. [5] WU F,CHEN Z,LIU J B,et al.The Akt-mTOR network at the interface of hematopoietic stem cell homeostasis[J]. Exp Hematol,2021,103:15-23. [6] HO A D.Kinetics and symmetry of divisions of hematopoietic stem cells[J]. Exp Hematol, 2005,33(1):1-8. [7] YANG L P,BRYDER D,ADOLFSSON J,et al.Identification of Lin (-) Sca1(+)kit(+)CD34+Flt3- short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients[J]. Blood,2005,105(7):2717-2723. [8] CHENG H,ZHENG Z F,CHENG T.New paradigms on hematopoietic stem cell differentiation[J]. Protein Cell,2020,11(1):34-44. [9] SPEVAK C C,ELIAS H K,KANNAN L,et al. Hematopoietic stem and progenitor cells exhibit stage-specific translational programs via mTOR- and CDK1-dependent mechanisms[J]. Cell Stem Cell,2020,26(5):755-765.e7. [10] GUO F K,ZHANG S M,GROGG M,et al.Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis[J]. Haematologica,2013,98(9):1353-1358. [11] MALIK N,SANSOM O J,MICHIE A M.The role of mTOR-mediated signals during haemopoiesis and lineage commitment[J]. Biochem Soc Trans, 2018, 46(5):1313-1324. [12] QIAN P X,HE X C,PAULSON A,et al.The Dlk1-Gtl2 locus preserves LT-HSC function by inhibiting the PI3K-mTOR pathway to restrict mitochondrial metabolism[J]. Cell Stem Cell,2016,18(2):214-228. [13] VAN GALEN P,KRESO A,WIENHOLDS E,et al.Reduced lymphoid lineage priming promotes human hematopoietic stem cell expansion[J]. Cell Stem Cell, 2014,14(1):94-106. [14] FINGAR D C,BLENIS J.Target of rapamycin (TOR):an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression[J]. Oncogene,2004,23(18):3151-3171. [15] WEICHHART T. mTOR as regulator of lifespan, aging, and cellular senescence:a mini-review[J]. Gerontology, 2018,64(2):127-134. [16] JHANWAR-UNIYAL M,WAINWRIGHT J V,MOHAN A L,et al.Diverse signaling mechanisms of mTOR complexes:mTORC1 and mTORC2 in forming a formidable relationship[J]. Adv Biol Regul,2019,72:51-62. [17] SAXTON R A,SABATINI D M. mTOR signaling in growth, metabolism, and disease[J]. Cell,2017,168(6): 960-976. [18] MANNING B D,TOKER A.AKT/PKB signaling: navigating the network[J]. Cell,2017,169(3):381-405. [19] JACINTO E,LOEWITH R,SCHMIDT A,et al.Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive[J]. Nat Cell Biol,2004,6(11):1122-1128. [20] IKENOUE T,INOKI K,YANG Q,et al.Essential function of TORC2 in PKC and Akt turn motif phosphorylation,maturation and signalling[J]. EMBO J, 2008,27(14):1919-1931. [21] HOSHII T,MATSUDA S,HIRAO A.Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis[J]. J Biochem,2014,156(2):73-83. [22] WU X L,WANG L K,YANG D D,et al.Effects of Glut1 gene silencing on proliferation,differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway[J]. J Cell Biochem, 2018,119(2):2356-2367. [23] SHARIF O,BRUNNER J S,VOGEL A,et al.Macrophage rewiring by nutrient associated PI3K dependent pathways[J]. Front Immunol,2019,10:2002. [24] SARRAZY V,VIAUD M,WESTERTERP M,et al.Disruption of Glut1 in hematopoietic stem cells prevents myelopoiesis and enhanced glucose flux in atheromatous plaques of ApoE (-/-) mice[J]. Circ Res, 2016, 118(7):1062-1077. [25] ALBERT B,TOMASSETTI S,GLOOR Y,et al.Sfp1 regulates transcriptional networks driving cell growth and division through multiple promoter-binding modes[J]. Genes Dev,2019,33(5/6):288-293. [26] SAKI N,JALALIFAR M A,SOLEIMANI M,et al.Adverse effect of high glucose concentration on stem cell therapy[J]. Int J Hematol Oncol Stem Cell Res, 2013,7(3):34-40. [27] CHEN X,YU C Y,LIU X H,et al.Intracellular galectin-3 is a lipopolysaccharide sensor that promotes glycolysis through mTORC1 activation[J]. Nat Commun, 2022, 13(1):7578. [28] CHUNG J,BAUER D E,GHAMARI A,et al. The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability[J]. Sci Signal, 2015,8(372):ra34. [29] OBUROGLU L,ROMANO M,TAYLOR N,et al.Metabolic regulation of hematopoietic stem cell commitment and erythroid differentiation[J]. Curr Opin Hematol,2016,23(3):198-205. [30] ITO K,CARRACEDO A,WEISS D,et al.A PML-PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance[J]. Nat Med,2012,18(9):1350-1358. [31] KALAITZIDIS D,SYKES S M,WANG Z,et al.mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis[J]. Cell Stem Cell, 2012,11(3):429-439. [32] MAGEE J A,IKENOUE T,NAKADA D,et al.Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression[J]. Cell Stem Cell,2012,11(3):415-428. [33] MONSALVE A,CANALS I,OBUROGLU L.FOXO1 regulates pentose phosphate pathway-mediated induction of developmental erythropoiesis[J]. Front Cell Dev Biol,2022,10:1039636. [34] CAPITANO M L,BROXMEYER H E.A role for intracellular and extracellular DEK in regulating hematopoiesis[J]. Curr Opin Hematol,2017,24(4):300-306. [35] CHEN Z,HUO D W,LI L,et al.Nuclear DEK preserves hematopoietic stem cells potential via NCoR1/HDAC3-Akt1/2-mTOR axis[J]. J Exp Med,2021,218(5): e20201974. [36] LIANG R,ARIF T,KALMYKOVA S,et al. Restraining lysosomal activity preserves hematopoietic stem cell quiescence and potency[J]. Cell Stem Cell,2020,26(3): 359-376.e7. [37] LIU L,INOKI A,FAN K,et al.ER-associated degradation preserves hematopoietic stem cell quiescence and self-renewal by restricting mTOR activity[J]. Blood,2020, 136(26):2975-2986. [38] BUITENHUIS M,COFFER P J.The role of the PI3K-PKB signaling module in regulation of hematopoiesis[J]. Cell Cycle,2009,8(4):560-566. [39] ZHANG J W,GRINDLEY J C,YIN T,et al.PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention[J]. Nature,2006, 441(7092):518-522. [40] ZHENG L,PAN C,TIAN W L,et al.Atp8a1 deletion increases the proliferative activity of hematopoietic stem cells by impairing PTEN function[J]. Cell Oncol,2023, 46(4):1069-1083. [41] CHEN C,LIU Y,LIU R H,et al.TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species[J]. J Exp Med,2008,205(10):2397-2408. [42] SIEGEMUND S,RIGAUD S,CONCHE C,et al.IP3 3-kinase B controls hematopoietic stem cell homeostasis and prevents lethal hematopoietic failure in mice[J]. Blood,2015,125(18):2786-2797. [43] LIU Q,LUO L H,REN C H,et al.The opposing roles of the mTOR signaling pathway in different phases of human umbilical cord blood-derived CD34+ cell erythropoiesis[J]. Stem Cells,2020,38(11):1492-1505. [44] PENG H,KASADA A,UENO M,et al.Distinct roles of Rheb and Raptor in activating mTOR complex 1 for the self-renewal of hematopoietic stem cells[J]. Biochem Biophys Res Commun,2018,495(1):1129-1135. [45] WANG X M,GAO Y N,GAO J,et al.Rheb1 loss leads to increased hematopoietic stem cell proliferation and myeloid-biased differentiation in vivo[J]. Haematologica, 2019,104(2):245-255. [46] BUECHLER M B,AKILESH H M,HAMERMAN J A.Cutting edge:direct sensing of TLR7 ligands and type Ⅰ IFN by the common myeloid progenitor promotes mTOR/PI3K-dependent emergency myelopoiesis[J]. J Immunol,2016,197(7):2577-2582. [47] BONO C,GUERRERO P,ERADES A,et al.Direct TLR2 signaling through mTOR and TBK1 induces C/EBPβ and IRF7-dependent macrophage differentiation in hematopoietic stem and progenitor cells[J]. Stem Cells, 2022,40(10):949-962. [48] TROWBRIDGE J J,XENOCOSTAS A,MOON R T,et al.Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation[J]. Nat Med,2006, 12(1):89-98. [49] KAO C Y,JIANG J L,THOMPSON W,et al.MiR-486-5p and miR-22-3p enable megakaryocytic differentiation of hematopoietic stem and progenitor cells without thrombopoietin[J]. Int J Mol Sci,2022,23(10):5355. [50] YAMASHITA M,DELLORUSSO P V,OLSON O C,et al.Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis[J]. Nat Rev Cancer,2020, 20(7):365-382. [51] LIU H C,HUSSAIN Z,XIE Q Q,et al.Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax[J]. Exp Cell Res,2022,417(2): 113192. [52] OSMAN N,ELZAYAT R,ELTOUNSI I.Higher mTOR expression:a marker of poor outcome in patients with de novo AML[J]. Indian J Hematol Blood Transfus,2023, 39(2):325-329. [53] FENG Y H,WU L S. mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival[J]. Biochem Biophys Res Commun,2017,483(2):897-903. [54] ANNUNZIATA M,BONIFACIO M,BRECCIA M,et al.Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia[J]. Front Oncol,2020,10:883. [55] LY C,ARECHIGA A F,MELO J V,et al.Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin[J]. Cancer Res, 2003,63(18):5716-5722. [56] CARAYOL N,VAKANA E,SASSANO A,et al.Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells[J]. Proc Natl Acad Sci U S A,2010,107(28):12469-12474. [57] CHU S H,HEISER D,LI L,et al.FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm[J]. Cell Stem Cell,2012,11(3):346-358. [58] PALUMBO G A,STELLA S,PENNISI M S,et al.The role of new technologies in myeloproliferative neoplasms[J]. Front Oncol,2019,9:321. [59] BARTALUCCI N,TOZZI L,BOGANI C,et al.Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms[J]. J Cell Mol Med,2013,17(11):1385-1396. [60] DAL COL J,ZANCAI,TERRIN L,et al.Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma[J]. Blood,2008, 111(10):5142-5151. |
[1] | ZHUANG Yuan, YU Yang. Strengthening the Application of Centrifugal Technology and Establishing a Combined Apheresis/Blood Purification System in the Department of Transfusion Medicine [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 721-725. |
[2] | LIU Xiaomin, ZHUANG Yuan, YU Yang. Survey Report on Current Status of Transfusion Therapy in Transfusion Medicine Departments of Medical Institutions Across China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 740-743. |
[3] | SHEN Qianyun, CHENG Wenguo, HOU Shuning, YAO Genghong. Differential Expression and Clinical Significance of Vascular Cell Adhesion Molecule-1 in Plasma of Neonates with ABO Hemolytic Disease [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 744-749. |
[4] | WANG Danting, LONG Honghui, NIU Yingying, HUANG Chunyan. Analysis and Clinical Significance of Minor Cross-match Incompatibility with Micro-column Gel Test [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 750-754. |
[5] | CHE Yang, LIU Zheng, ZHOU Xiaoyu. Retrospective Analysis of the Efficacy of Postoperative Plasma Transfusion in Patients with Primary Liver Cancer Undergoing Liver Resection [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 755-761. |
[6] | ZHENG Yan, WANG Wenting, YANG Longfei, WANG Qiong, MU Shijie. Serological Characteristics and DNA Sequence Analysis of Patients with RhD Variant [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 762-765. |
[7] | LIANG Chunyan, DUAN Li, LIU Youying, LIU Fangjiu. Risk Factors and Predictive Models of Transfusion-associated Circulatory Overload in Hospitalized Patients [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 771-776. |
[8] | CAI Yin, CHEN Zhiying, JIANG Ling, REN Yana, ZHENG Lan, ZHOU Guoping. Screening Analysis of HLA Antibodies of Blood Donors in Shanghai Area [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 777-780. |
[9] | GUO Rui, HOU Yun, SU Changshan, et al. Assessing the Residual Risk of Hepatitis B Virus Transmission via Blood Transfusion in 21 Chinese Blood Centers from 2018 to 2022 [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 781-786. |
[10] | LI Yan, ZHOU Liling, MA Zhaoze, ZHU Kaijie, WANG Chenlong. Genotypic Identification and Sequence Analysis of B/AB Subtypes in 25 Cases [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 787-791. |
[11] | LI Xin, YANG Junhong. Meta Analysis of Incidence of Platelet Antibody in Pregnant Women in China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 805-811. |
[12] | MING Jing, DING Kaiyang, HU Maogui, WANG Xinchen. Efficacy of Avatrombopag Combined with rhTPO for Thrombocytopenia Treatment in Patients with Hematologic Malignancies after Autologous Hematopoietic Stem Cell Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 812-817. |
[13] | WANG Shujun, LI Zhaojie, YANG Yi, LUAN Jianfeng. Platelet-derived Products in Wound Healing [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 825-834. |
[14] | REN Daoju, LI Xiaowei, LI Cuiying. Advances in Non-invasive Cell-free Fetal DNA Blood Group Testing in Prenatal Diagnosis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 835-842. |
[15] | . [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 843-848. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||